The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding.
about
Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1Membrane Potential and Calcium Dynamics in Beta Cells from Mouse Pancreas Tissue Slices: Theory, Experimentation, and AnalysisThe action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice.DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-Cells dysfunction in db/db miceInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Sweet taste receptors regulate basal insulin secretion and contribute to compensatory insulin hypersecretion during the development of diabetes in male mice.Glucolipotoxicity of the pancreatic beta cell.Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice.Lipid receptors and islet function: therapeutic implications?Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion.A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.Defective insulin secretory response to intravenous glucose in C57Bl/6J compared to C57Bl/6N mice.Inhibition of Id1 augments insulin secretion and protects against high-fat diet-induced glucose intolerance.Fish Oil Accelerates Diet-Induced Entrainment of the Mouse Peripheral Clock via GPR120.Elevated nocturnal NEFA are an early signal for hyperinsulinaemic compensation during diet-induced insulin resistance in dogs.Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases.Free fatty acid receptors: emerging targets for treatment of diabetes and its complications.Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptorThe G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin.GPR40 modulators: new kid on the blockRandomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes.Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1.Failure of the adaptive unfolded protein response in islets of obese mice is linked with abnormalities in β-cell gene expression and progression to diabetesDisruption of the sugar-sensing receptor T1R2 attenuates metabolic derangements associated with diet-induced obesityLack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease.GPR40: good cop, bad cop?Drugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRsOleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems.Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets.Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.Molecular mechanisms underlying nutrient detection by incretin-secreting cells.Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders.Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease.Minireview: The effects of species ortholog and SNP variation on receptors for free fatty acids.Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.Fasiglifam as a new potential treatment option for patients with type 2 diabetes.The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism.GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
P2860
Q24629432-45303341-EF49-4147-83A1-F9817DA5E3C1Q26777794-AC459422-8367-48CF-BE3A-DDD85AE39339Q27865233-31D2AF6C-5A99-4E4A-90E3-D186DDC2D9C9Q27865234-4720988F-95A8-4AD5-8BFA-273C3AA7FBBDQ28533802-7BB86C6D-7281-4E5C-873C-C229E659D3F8Q30426407-60486842-73A5-4684-AFC8-B33433A3122AQ33610629-CAF32197-B157-41E1-A13C-9EE73602AE9AQ33665283-7FA098E4-ADBA-47C6-8796-1878F1F91C4FQ33718447-CAEBFCF8-D42D-4B7B-8345-1C9CAF2CF4C2Q33930824-993F78DB-FFAB-44C7-AF52-8B94C0A03706Q34076033-E6166889-CE0B-4162-AD60-9D49661CCA26Q34441309-85E92506-5C81-40AF-9746-0E14038C0A5CQ34687550-67A87549-16D5-40C2-825B-18B1A2F2AB57Q35227161-EFBC6D8B-C55D-473F-A10A-D35B6C03B6B1Q35687964-4DB60CF0-D616-49C5-A684-166FE1577D69Q36113667-B478A1F8-ACFB-42A7-B805-2046CE8B17E4Q36165684-BDC38E9B-BD96-4312-9903-71D04FFDEA47Q36327956-76F6C6C3-E7F4-48D8-A230-6A0B377954BAQ36335625-587C6DDA-E20A-4EBE-8AF4-8E06E42175E9Q36477035-B7978B45-289F-418C-9F2D-6E0EF60ECAA5Q36560325-C0727866-03C4-431D-B470-232B3338E05BQ36560412-43CCD4F0-1090-41DB-8C10-1B73216FDBC6Q36772416-2F23F794-47E9-4A6E-B989-3DB85D5EA2A5Q36796096-4DEA4AFA-5D36-4C80-BD0B-03361838B8ABQ36810761-47930FB4-C17D-4C64-9F9B-6C4BDC0EF357Q36943727-326D3C78-9F00-4FB7-B936-F21BFBC8A014Q37163504-6930F234-920C-4BF0-A510-D9942C16ED58Q37237145-DC9E11BA-75E5-4DBE-A8ED-A80928949C83Q37253051-88A5CDF7-0309-4252-B271-D71F625DBB14Q37400740-830EC293-9201-495A-BA63-3F7B7960C44BQ37481309-41C2A0C2-BC8B-4721-8802-C7C8BEA2F9F8Q37702790-94A129B9-CF3D-416B-89C0-5E0997C823AAQ37810292-2494017C-AA3C-48DE-B724-CEA4BB14AD36Q37911549-CF6D510C-A46E-45DD-BC9B-371CA0F65F57Q38067511-5373DFA2-AE84-466E-9E91-2E10A6CCA28EQ38107811-18869377-6321-4FD1-82AC-EB10FBDA4025Q38123792-5F9E8C8D-2C4B-4DB6-8111-A670102B58E4Q38160275-B0990352-00BE-4755-AF7A-C23BC4ACA441Q38259563-2A510652-D13F-4F5C-BF2B-DF75B7D837D0Q38325894-C46DE7E7-B0CE-4F02-BCE2-0382DFBE64B9
P2860
The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The fatty acid receptor GPR40 ...... n vivo after high-fat feeding.
@en
type
label
The fatty acid receptor GPR40 ...... n vivo after high-fat feeding.
@en
prefLabel
The fatty acid receptor GPR40 ...... n vivo after high-fat feeding.
@en
P2093
P2860
P50
P356
P1433
P1476
The fatty acid receptor GPR40 ...... in vivo after high-fat feeding
@en
P2093
Caroline Tremblay
Martin G Latour
Meriem Semache
P2860
P304
P356
10.2337/DB08-0553
P407
P577
2008-06-16T00:00:00Z